Doxazosin in a gastrointestinal therapeutic system formulation

Abstract

A new formulation of doxazosin, the gastrointestinal therapeutic system (GITS), has been developed to change the drug delivery rate and the pharmacokinetic profile of the drug, allowing a more gradual absorption of doxazosin, thus reducing the plasma doxazosin trough-to-peak ratio and minimizing the need for titration. In patients with hypertension or symptomatic benign prostatic hypertrophy, doxazosin GITS is efficacious as doxazosin standard formulation but has better tolerance and eliminates the need for titration.